This is a working overview of thymus extract, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-27 and is reviewed periodically as new material appears.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
=== Bibliography === Hodgson, David (October 2004). Half Life 2: Raising The Bar Uncorrected Proof. United States: Prima Games. ISBN 0-7615-4364-3. Valve Corporation; Sierra Studios (2000). Half-Life Counter-Strike Manual. Sierra.
TC/EA (or HTC, high temperature conversion; HTP, high temperature pyrolysis; HTCR, high temperature carbon reduction) is an "online" or "continuous flow" preparation method typically followed by IRMS detection. This is a "bulk" technique that measures all the hydrogen in a sample and provides the average isotope signal. The weighed sample is placed in a tin or silver capsule and dropped into a pyrolysis tube of TC/EA. The tube is made of glassy carbon with glassy carbon filling, so oxygen isotopes can be measured simultaneously without oxygen exchange with ceramic (Al2O3) surface. The molecules are then reduced into CO and H2 at high temperature (>1400°C) in the reactor. The gaseous products are separated through gas chromatography (GC) using helium as the carrier gas, followed by a split-flow interface, and finally detected by IRMS. TC/EA method can be problematic for organic compounds with halogen or nitrogen due to the competition between the pyrolysis byproducts (e.g. HCl and HCN) and H2 formation. In addition, it is susceptible to contamination with water, so samples must be scrupulously dried. An adaption of this method is to determine the non-exchangeable (C-H) and exchangeable hydrogen (bounds to other elements, e.g. O, S and N) in organic matter. The samples are equilibrated with water in sealed autosampler carousels at 115°C and then transferred into pyrolysis EA followed by IRMS measurement. TC/EA method is quick with fairly high precision (~1‰).
Adolfo Suárez formed a government of young Francoist "reformists", in which he did not include any prominent figures ─ Fraga and Areilza, refused to participate ─ but which did not lack political experience. In his first statement, made before the TVE cameras, the new president presented his "reformist" project which contained important novelties of language and objectives and which caused a great impact on the majority of the population. He stated that his goal was to achieve "that the governments of the future be the result of the free will of the majority of Spaniards" and, after expressing his conviction that sovereignty resided in the people, he announced that they would express themselves freely in a general election to be called for before June 30 of the following year. It was a matter of "elevating to the category of normal what at street level is simply normal." Finally, Suárez announced that the "political reform" to be undertaken would be submitted to a referendum. The Political Reform Act bill, which was drafted jointly by the president of the Cortes, Torcuato Fernández Miranda, the vice-president of the government Alfonso Osorio and the Minister of Justice Landelino Lavilla, was very simple. A new Cortes was created, consisting of two chambers, the Congress of Deputies and the Senate, composed of 350 and 204 members respectively and elected by universal suffrage, except for the senators appointed by the king. And at the same time, all the institutions established in the fundamental laws other than the Cortes were implicitly abolished, i.e.
Sources: en.wikipedia.org
=== PVA/PAMPS hydrogel === In 2020, developers combined a bacterial cellulose nanofiber network with a poly(vinyl alcohol) (PVA) - poly(2-acrylamido-2-methyl-1-propanesulfonic acid sodium salt) (PAMPS) double network hydrogel. The artificial cartilage displayed the same strength and modulus as natural cartilage in terms of tension and compression, and was the first lab-created option to exhibit cartilage-equivalent tensile fatigue strength. The hydrogel needs to undergo further lab testing before researchers determine if it can be moved to clinical use. PVA hydrogels prepared by several freezing-thawing, without an externally added crosslinking agent, have also exhibited great promises in terms of biocompatibility, wear resistance, shock absorption, friction coefficient, flexibility, and lubrication (due to uptake/excretion of body fluid). A two-year implantation of the PVA gels as artificial meniscus in rabbits showed that they remain intact without degradation, fracture, or loss of properties.
Hyaline cartilage is the glass-like (hyaline) and translucent cartilage found on many joint surfaces. It is also most commonly found in the ribs, nose, larynx, and trachea. Hyaline cartilage is pearl-gray in color, with a firm consistency and has a considerable amount of collagen. It contains no nerves or blood vessels, and its structure is relatively simple.
250No In 2003, scientists at the FLNR reported that they had been able to synthesise 249No, which decayed by SF with a half-life of 54 μs. Further work in 2006 by scientists at the ANL showed that the activity was actually due to a K-isomer in 250No. The ground state isomer was also detected with a very short half-life of 3.7 μs.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.